HMGB1 and systemic sclerosis: Current molecular targets of SSc endothelium dysregulation are endothelin−1, platelet−derived growth factor (PDGF) signalling, 5−hydroxytryptamine and VEGF [40], while HMGB1 may be also a potential target for SSc from the collected data.